Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Gains from Sales and Divestitures: 2015-2022

Historic Gains from Sales and Divestitures for Arrowhead Pharmaceuticals (ARWR) over the last 7 years, with Mar 2022 value amounting to $931,063.

  • Arrowhead Pharmaceuticals' Gains from Sales and Divestitures rose 13.05% to $931,063 in Q1 2022 from the same period last year, while for Mar 2022 it was $931,063, marking a year-over-year increase of 13.05%. This contributed to the annual value of $899,025 for FY2021, which is 22.42% down from last year.
  • According to the latest figures from Q1 2022, Arrowhead Pharmaceuticals' Gains from Sales and Divestitures is $931,063, which was up 253.08% from $263,700 recorded in Q4 2021.
  • Arrowhead Pharmaceuticals' 5-year Gains from Sales and Divestitures high stood at $2.2 million for Q1 2019, and its period low was $263,700 during Q4 2021.
  • Its 3-year average for Gains from Sales and Divestitures is $813,247, with a median of $899,025 in 2021.
  • In the last 5 years, Arrowhead Pharmaceuticals' Gains from Sales and Divestitures spiked by 6,489.59% in 2018 and then plummeted by 56.52% in 2020.
  • Arrowhead Pharmaceuticals' Gains from Sales and Divestitures (Quarterly) stood at $658,959 in 2018, then declined by 19.06% to $533,333 in 2019, then crashed by 47.44% to $280,325 in 2020, then fell by 5.93% to $263,700 in 2021, then climbed by 13.05% to $931,063 in 2022.
  • Its Gains from Sales and Divestitures stands at $931,063 for Q1 2022, versus $263,700 for Q4 2021 and $899,025 for Q3 2021.